GlassScriptPhysician profile
Anthony Adamo
NPI 1992817456
$8,413.80
in general payments reported to CMS, 2019-2025
38 companies · $1,331 in 2025
The $1,331 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $1,032 · 2021: $1,639 · 2022: $1,646 · 2023: $1,023 · 2024: $1,336 · 2025: $1,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,673 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,673.43 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,652.41 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Abbvie INC. | $1,576.08 | 2021-2025 | Qulipta, Ubrelvy |
| Eisai INC. | $920.40 | 2019-2022 | |
| Ucb, INC. | $512.92 | 2019-2025 | Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $403.70 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $378.85 | 2020-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $357.42 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $291.67 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $281.14 | 2023-2025 | |
| Amgen INC. | $221.40 | 2021-2025 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $187.53 | 2022 | |
| Genzyme Corporation | $171.95 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $170.61 | 2020-2023 | Ongentys, Ingrezza |
| Sk Life Science, INC. | $122.07 | 2020-2024 | |
| Emd Serono, INC. | $118.87 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $86.75 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $86.20 | 2022 | |
| Corium, LLC | $83.53 | 2023 | Adlarity |
| Biohaven Pharmaceuticals, INC. | $82.05 | 2020-2021 | |
| Amylyx Pharmaceuticals, INC. | $79.50 | 2023-2024 | Relyvrio |
| Grifols USA, LLC | $69.19 | 2019-2024 | Gamunex-C |
| Medtronic, INC. | $64.11 | 2024-2025 | Percept PC Brainsense |
| Lilly USA, LLC | $56.61 | 2020-2022 | |
| Celgene Corporation | $53.89 | 2020-2021 | |
| Catalyst Pharmaceuticals, INC. | $53.25 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $45.36 | 2020-2021 | |
| Genentech USA, INC. | $39.27 | 2019-2025 | Ocrevus Zunovo |
| Almatica Pharma LLC | $36.16 | 2021 | |
| Adamas Pharmaceuticals, INC. | $34.93 | 2021 | |
| Lundbeck LLC | $29.04 | 2020-2022 | |
| Allergan, INC. | $25.03 | 2020 | |
| Impel Pharmaceuticals INC. | $20.91 | 2023 | Trudhesa |
| Neurelis, INC. | $20.00 | 2020 | |
| Kyowa Kirin, INC. | $19.15 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.74 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.77 | 2025 | Wainua |
| Azurity Pharmaceuticals, INC. | $13.64 | 2022 | |
| Assertio Therapeutics, INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Adamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.